Prof Michael Lisanti to speak at one of the world's leading cancer research institutes
Mar 09, 2017
Chair in Translational Medicine Prof Michael Lisanti is to speak at the inauguration of one of the world’s most significant new cancer research institutes.
The newly-established Forbes Institute for Cancer Discovery at the University of Michigan will “lead new avenues of cancer therapy” with support from philanthropists Madeleine and Sidney Forbes.
Michael is one of just four specialists invited to present his research at the Forbes-Taubman Symposium in Ann Arbor, Michigan, on March 17 – and is the sole non-North American based speaker.
He will share the podium with some of the leading experts in the field of cancer stem cell research, including Max Wicha, MD, Distinguished Professor of Oncology and the pre-eminent specialist in the US.
Michael, a graduate in cell biology and genetics, specialises in cancer metabolism and cell signaling and is a past fellow at the Whitehead Institute at MIT and has held distinguished posts at the Albert Einstein College of Medicine, the Kimmel Center, and the Breakthrough Breast Cancer Research Unit at The University of Manchester.
He joined us in August 2016 and is building a new team in Translational Medicine and Oncology, specialising in treatments which target the growth and survival of cancer stem cells (CSCs).
His team, which includes Dr Gloria Bonucelli and Dr Marco Fiorillo, last month published a paper providing evidence that CSCs proliferate more quickly than previously proved, and they have most recently published evidence that Vitamin C has a significant impact on CSC growth.
Professor Lisanti also actively collaborates with several other oncology research teams at Salford, led by Professor Marija Krstic-Demonacos and Professor Luciano Mutti, as well as Reader Dr. Federica Sotgia.